Prajmalium
CARDIOVASCULAR SYSTEM
Also known as: N-Propylajmaline, N-Propylajmalinium, N4-Propylajmalinium, prajmaline, prajmaline bitartrate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Prajmalium is a drug catalogued in DrugCentral. Recorded indications include Ventricular arrhythmia.
- Indications: Ventricular arrhythmia.
- ATC code: C01BA08 (Antiarrhythmics, class Ia).
- Molecular formula: C23H33N2O2; molecular weight 369.53 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Ventricular arrhythmia
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C01BA08 | CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class Ia |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Prajmalium is on its molecule page.
| Molecular formula | C23H33N2O2 |
|---|---|
| Molecular weight | 369.53 g/mol |
| CAS number | 35080-11-6 |
| InChIKey | UAUHEPXILIZYCU-ALHOSYKFSA-N |
| PubChem CID | 76959818 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Prajmalium used for?
DrugCentral lists the following indications for Prajmalium: Ventricular arrhythmia.
What is the chemical formula of Prajmalium?
Prajmalium has the molecular formula C23H33N2O2 and a molecular weight of 369.53 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2230 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3833382 — compound record and bioactivity
- PubChem CID 76959818 — chemical identifiers
- DrugBank DB13555 — drug record
- FDA UNII 75934UD4GJ — substance identity
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.